The new strain of the mpox virus is rapidly spreading along the eastern border of the Democratic Republic of Congo and has been labeled as the “most dangerous yet” by the World Health Organization. The outbreak has been primarily driven by sexual transmission, but recent evidence suggests that this strain can also be transmitted through close skin-to-skin contact. This alarming development has led to infections among various demographics, including schoolchildren, healthcare workers, and entire households. The situation has escalated to the extent that even South Africa has reported outbreaks that have resulted in the deaths of three individuals. Border authorities are on high alert, screening travellers both entering and exiting the country to prevent further spread of the virus.
Mpox, previously known as monkeypox, is a pox virus that was first identified in laboratory monkeys exported from Africa in the 1950s. The first human cases were documented in the 1970s in the Democratic Republic of Congo, where small animals like monkeys and rodents transmitted the disease to humans, hence the name monkeypox. The symptoms of mpox are varied and can initially mimic common viral illnesses, including fatigue, aches, fever, headache, respiratory symptoms, and a distinctive rash. The rash associated with mpox progresses from itchy and painful blisters to scabbing over, with the fluid in these blisters being highly infectious. It is crucial to note that some individuals may exhibit only a few blisters, which can be challenging to discern depending on their location, while others may display no symptoms at all.
As the mpox outbreak continues to gain momentum, it has spread beyond the borders of Africa and into 116 countries worldwide. The World Health Organization declared mpox a public health emergency of international concern in July 2022, underscoring the gravity of the situation. This pandemic has highlighted several critical concerns that demand immediate attention. Firstly, mpox is now rapidly transmitting from person to person without a clear understanding of the underlying mechanisms. The sustained transmission has led to faster mutations of the virus, resulting in the emergence of new sub-clades. Furthermore, there is currently no licensed, mpox-specific vaccine available to prevent infections, nor are there targeted antiviral drugs to treat severe cases effectively.
To effectively combat the mpox crisis, a multifaceted approach is required. Enhanced communication efforts by healthcare agencies are imperative to educate the public on transmission methods, testing locations, and risk mitigation strategies. Lessons from previous pandemics, such as the HIV/AIDS crisis, emphasize the importance of destigmatizing mpox to facilitate widespread testing and treatment access. Additionally, the development of a tailored vaccine, such as the mRNA vaccine candidate currently in clinical trials, is crucial to prevent new infections and curb the spread of the virus.
The emergence of mpox as a global health threat can be attributed to various factors, including the waning immunity against related viruses like smallpox. The discontinuation of routine smallpox vaccinations over four decades ago has rendered a significant portion of the population susceptible to mpox infections. As a result, the virus can now spread unchecked among individuals, underscoring the urgent need for comprehensive vaccination campaigns and enhanced surveillance measures. By prioritizing the development of effective vaccines, treatment protocols, and prevention strategies, we can mitigate the impact of the mpox pandemic and safeguard global public health.
Leave a Reply